This study builds on a cost of illness study for refractory asthma in the UK conducted in 2013 that used data from British Thoracic Society (BTS) Difficult Asthma Registry.
This study will use the UK’s Optimum Patient Care Research Database (OPCRD) to address a number of objectives relating to refractory asthma in the UK. The findings of the OPCRD evaluations will be compared to those of the BTS Difficult Asthma Registry morbidity prevalence data to help provide best morbidity prevalence estimates for the UK’s refractory asthma populations and to inform the development of models to estimate the burden of steroid-induced morbidity.
The OPCRD will be used to:
(1) Evaluate the prevalence of steroid-induced morbidities in patients with refractory asthma compared to the prevalence with patients with well-controlled asthma and among non-asthmatic controls. Morbidity rates will be stratified by:
a. Asthma severity: refractory asthma vs well-controlled asthma vs non-asthma controls
b. Age & Gender (12-20;21-30;31-40;41-50;51-60;61-70;70+)
(2) Evaluate the new incidence rate of morbidities in patients with refractory asthma vs well-controlled asthma vs non-asthma controls
Combining data from the OPCRD and the BTS Difficult Asthma Registry:
(3) Morbidity rates in refractory asthma patients will be compared and contrasted.
(4) Using data from (1) and (3), up-to-date UK prevalence rates for potential steroid-induced morbidities will be provided for patients with refractory asthma vs well-controlled asthma.
(5) Based on (2) and (4):
a. The annual cost associated with the treatment and management of systemic steroid-induced morbidities will be estimated
b. A model estimating the lifetime cost of morbidity attributable to systemic steroid exposure, will be developed.
Liam Heaney, Centre for Infection and Immunity, Queens University Belfast, Belfast, UK
Joan Sweeney: Centre for Infection and Immunity, Queen’s University Belfast, Belfast, UK
Christopher Patterson: Centre for Public Health, Queen’s University Belfast, Belfast, UK
David Price: Primary Care Respiratory Society UK, Professor of Primary Care Respiratory Medicine, University of Aberdeen, UK; Director Optimum Patient Care Ltd and Research in Real Life Ltd
Alison Chisholm: Respiratory Effectiveness Group Implementation Manager